Although current antiretroviral therapy prolongs the life of HIV-infected individuals, it does not fully restore health. These drugs often have significant toxicities. Many individuals are not able to maintain long-term adherence necessary to maintain benefit. The drugs are expensive and are not available to most of the people globally who need them. To reverse the spread of the epidemic and to provide care for all, a fundamentally different approach is needed. One such approach would be to identify a means to cure HIV-infected people with a safe and scalable intervention. Despite complete or near complete inhibition of viral replication with standard therapies, replication-competent HIV persists indefinitely in all individuals. There are at least three mechanisms that contribute to this persistence: (1) maintenance of transcriptionally-silent proviral genomes within long-lived CD4+ T cells and myeloid cells, (2) proliferation of latently-infected cells with regeneration of a stable reservoir of slowly-dividing infected cells, and/or (3) tissue-based foci of viral replication and cell-to-cell spread that may be driven in part by local inflammatory responses. Our proposal has three broadly defined objectives that are aimed at understanding the nature of HIV persistence and reversing latency. First, we will define the anatomic and cellular distribution of replication-competent virus resides during long-term therapy. Second, we will investigate the host mechanisms that contribute to the establishment and maintenance of HIV latency, focusing on the role that cell-to-cell interactions have in silencing the transcription of integrated HIV DNA and/or otherwise maintaining its persistence. Third, we will develop and test (in non-human primates and in humans) targeted interventions aimed at reversing latency without broadly activating the immune system and/or DNA transcription. To address these objectives, we have assembled a group of investigators who have a long track record of successful collaboration, with each other and with others, and who believe that a cure will ultimately depend in part on modifying HIV-associated host responses that directly contribute to viral latency.
The major barrier to curing HIV infection is a reservoir of long-lived cells that contain replication-competent virus. We believe that a comprehensive assessment of the reservoir together with the in vivo testing of possible interventions aimed at reversing this process will almost certainly advance the field, and could in five years provide the rationale for advanced testing in humans of single or combination regimens aimed at fully eradicating HIV from an infected person. Project 1: Myeloid- T Cell Interactions That Sustain SIV Reservoirs During Effective Antiretroviral Therapy Project Leader (PL): Dr. Joseph McCune (Description as provided by applicant) HIV persistence in the optimally-treated patient is sustained by the maintenance of transcriptionally-silent proviral genomes within cell populations that are long-lived or that turn over slowly, and/or by ongoing low-level viral replication leading to de novo infection of target cells. It is a central theme of this Collaboratory that such persistence/latency of HIV is maintained by tissue-based interactions between CD4[+] T cells and myeloid cells through one or more mechanisms, including: (1) efficient cell-to-cell transfer of HIV;(2) regulatory signals that result in CD4[+] T cell dysfunction and impairment of the antiviral response;(3) myeloid signaling to CD4[+] T cells that results in maintenance of transcriptional silencing;and (4) inflammatory signals which result in CD4[+] T cell activation and increased risk of either de novo infection or reactivation of latently infected cells and replenishment of long-lived infected cells. Additionally, HIV infection may induce factors that promote survival of infected cells and, hence, of a long-lived viral reservoir. To determine which of these mechanisms are operative, we will first systemically interrogate the tissue spaces of the optimally treated host, so that the location and size of the latent and actively replicating reservoir can be determined. Given the availability of therapeutic agents that impact upon these mechanisms, we will then test definitively to what extent they might contribute to virus persistence/latency, alone or in concert. In this Project, this approach is taken in the context of SIV infection of the rhesus macaque (Macaca mulatta), pursuing experiments in the following Specific Aims: (1) to determine whether and how foci of persistently replicating and/or latent virus are sustained in the optimally-treated host by pathologic myeloid-T cell interactions;(2) to determine whether the persistent/latent virus pool can be diminished by inhibition of indoleamine 2,3-dioxygenase (IDO), an immunoregulatory enzyme that mediates the pro-inflammatory effects of myeloid cells on CD4+ T cells;and (3) to determine whether the persistent/latent virus pool can be diminished by inhibition of monocyte colony stimulating factor (MCSF), a cytokine which is upregulated by SIV/HIV and that prevents apoptosis of macrophages. RELEVANCE: Interacting closely with the work in Projects 2-5 and 7, this Project will explore the extent to which various interactions between CD4'T cells and myeloid cells are associated with persistence/latency of SIV virus after the initiation of ART. We will also develop a quantitative framework by which to assess changes in the total body load of viral genomes, before and after each mechanism is interrupted pharmacologically in vivo.
|Tjiam, M Christian; Morshidi, Mazmah A; Sariputra, Lucy et al. (2017) Association of HIV-1 Gag-Specific IgG Antibodies With Natural Control of HIV-1 Infection in Individuals Not Carrying HLA-B*57: 01 Is Only Observed in Viremic Controllers. J Acquir Immune Defic Syndr 76:e90-e92|
|Martin, Alyssa R; Pollack, Ross A; Capoferri, Adam et al. (2017) Rapamycin-mediated mTOR inhibition uncouples HIV-1 latency reversal from cytokine-associated toxicity. J Clin Invest 127:651-656|
|Power, Jennifer; Fileborn, Bianca; Dowsett, Gary W et al. (2017) HIV cure research: print and online media reporting in Australia. J Virus Erad 3:229-235|
|Winckelmann, Anni; Barton, Kirston; Hiener, Bonnie et al. (2017) Romidepsin-induced HIV-1 viremia during effective ART contains identical viral sequences with few deleterious mutations. AIDS :|
|Mota, Talia M; Rasmussen, Thomas A; Rhodes, Ajantha et al. (2017) No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. AIDS 31:1137-1141|
|Rasmussen, Thomas A; Anderson, Jenny L; Wightman, Fiona et al. (2017) Cancer therapies in HIV cure research. Curr Opin HIV AIDS 12:96-104|
|Kaiser, Philipp; Joshi, Sunil K; Kim, Peggy et al. (2017) Assays for precise quantification of total (including short) and elongated HIV-1 transcripts. J Virol Methods 242:1-8|
|Symons, Jori; Chopra, Abha; Malatinkova, Eva et al. (2017) HIV integration sites in latently infected cell lines: evidence of ongoing replication. Retrovirology 14:2|
|Tauriainen, Johanna; Scharf, Lydia; Frederiksen, Juliet et al. (2017) Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci Rep 7:40354|
|Seang, Sophie; Somasunderam, Anoma; Nigalye, Maitreyee et al. (2017) Circulating LOXL2 Levels Reflect Severity of Intestinal Fibrosis and GALT CD4+ T Lymphocyte Depletion in Treated HIV Infection. Pathog Immun 2:239-252|
Showing the most recent 10 out of 158 publications